IgA nephropathy, also known as “Berger’s disease,” is the most common form of glomerulonephritis worldwide. It is an immune-mediated kidney disease diagnosed based on urine test results and a kidney biopsy. Advances in research into the pathophysiological mechanisms have led to the development of innovative treatment strategies, for which some Phase IIIdata—including fusion proteins targeting the cytokines BAFF and/or APRIL, as well as selective endothelin A receptor antagonists and complement inhibitors. Furthermore, there is also interesting news regarding treatment options for IgAN that have also cleared regulatory hurdles in Europe.
Related Topics
- ALIGN
- APRIL
- Atacicept
- Atrasentan
- BAFF
- Berger's disease
- BION-1301
- Cigarette Mustache
- Complement inhibitors
- Cytokines
- Fusion proteins
- Glomerulonephritis
- IgA nephropathy
- immune-mediated kidney disease
- Kidney biopsy
- NEFIGAN
- NefIgArd
- NefXtend
- oral budesonide
- ORIGIN
- PROTECT
- Ravulizumab
- selective endothelin A receptor antagonists
- Sibeprenlimab
- Sparsentan
- Telitacicept
- Urinalysis Results
- VISIONARY
You May Also Like
- Endocrinology: APECED-Associated Hypoparathyroidism
A parathyroid hormone analog corrected serum calcium levels
- Transient ischemic attack
Comprehensive diagnostic testing can reduce the risk of stroke
- Malignant Tumors of the Clavicle
Surgical Challenges and Recurrence Patterns
- Chronic hand eczema: common, long-lasting, and distressing
Non-steroidal anti-inflammatory treatment options are essential for long-term management
- Alcohol Consumption While Taking Semaglutide
Withdrawal Symptoms Thanks to GLP-1 RA?
- Non-anginal chest pain: Could it be a heart attack?
From Triage to Secondary Prevention—A Recent Update
- Malignant oral squamous cell carcinomas (OPSCC/HNSCC)
Innovative Treatment Options
- Acne vulgaris: Topical and Systemic Treatment Options